These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Song H; Hollstein M; Xu Y Nat Cell Biol; 2007 May; 9(5):573-80. PubMed ID: 17417627 [TBL] [Abstract][Full Text] [Related]
25. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations. Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393 [TBL] [Abstract][Full Text] [Related]
26. p53 mutants without a functional tetramerisation domain are not oncogenic. Chène P; Bechter E J Mol Biol; 1999 Mar; 286(5):1269-74. PubMed ID: 10064694 [TBL] [Abstract][Full Text] [Related]
27. Inhibition of HIF-1- and wild-type p53-stimulated transcription by codon Arg175 p53 mutants with selective loss of functions. Blagosklonny MV; Giannakakou P; Romanova LY; Ryan KM; Vousden KH; Fojo T Carcinogenesis; 2001 Jun; 22(6):861-7. PubMed ID: 11375890 [TBL] [Abstract][Full Text] [Related]
28. p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay. Inga A; Monti P; Fronza G; Darden T; Resnick MA Oncogene; 2001 Jan; 20(4):501-13. PubMed ID: 11313981 [TBL] [Abstract][Full Text] [Related]
29. Folding of tetrameric p53: oligomerization and tumorigenic mutations induce misfolding and loss of function. Lubin DJ; Butler JS; Loh SN J Mol Biol; 2010 Jan; 395(4):705-16. PubMed ID: 19913028 [TBL] [Abstract][Full Text] [Related]
30. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Willis A; Jung EJ; Wakefield T; Chen X Oncogene; 2004 Mar; 23(13):2330-8. PubMed ID: 14743206 [TBL] [Abstract][Full Text] [Related]
31. Localization of a mutant p53 response element on the tissue inhibitor of metalloproteinase-3 promoter: mutant p53 activities are distinct from wild-type. Thomas S; Reisman D Cancer Lett; 2006 Aug; 240(1):48-59. PubMed ID: 16236433 [TBL] [Abstract][Full Text] [Related]
32. [Construction of chimeric tumor suppressor p53 resistant to the dominant-negative interaction with p53 mutants]. Almazov VP; Morgunkova AA; Kalinin VN; Kopnin BP; Prasolov VS; Chumakov PM Mol Biol (Mosk); 2002; 36(4):664-71. PubMed ID: 12173471 [TBL] [Abstract][Full Text] [Related]
33. Mechanisms of differential activation of target gene promoters by p53 hinge domain mutants with impaired apoptotic function. Kong XT; Gao H; Stanbridge EJ J Biol Chem; 2001 Aug; 276(35):32990-3000. PubMed ID: 11395510 [TBL] [Abstract][Full Text] [Related]
35. p53 domains: structure, oligomerization, and transformation. Wang P; Reed M; Wang Y; Mayr G; Stenger JE; Anderson ME; Schwedes JF; Tegtmeyer P Mol Cell Biol; 1994 Aug; 14(8):5182-91. PubMed ID: 8035799 [TBL] [Abstract][Full Text] [Related]
36. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance. Stiewe T; Haran TE Drug Resist Updat; 2018 May; 38():27-43. PubMed ID: 29857816 [TBL] [Abstract][Full Text] [Related]
37. Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. Wang Y; Suh YA; Fuller MY; Jackson JG; Xiong S; Terzian T; Quintás-Cardama A; Bankson JA; El-Naggar AK; Lozano G J Clin Invest; 2011 Mar; 121(3):893-904. PubMed ID: 21285512 [TBL] [Abstract][Full Text] [Related]
38. A dominant-negative effect drives selection of Boettcher S; Miller PG; Sharma R; McConkey M; Leventhal M; Krivtsov AV; Giacomelli AO; Wong W; Kim J; Chao S; Kurppa KJ; Yang X; Milenkowic K; Piccioni F; Root DE; Rücker FG; Flamand Y; Neuberg D; Lindsley RC; Jänne PA; Hahn WC; Jacks T; Döhner H; Armstrong SA; Ebert BL Science; 2019 Aug; 365(6453):599-604. PubMed ID: 31395785 [No Abstract] [Full Text] [Related]
39. The dihedral symmetry of the p53 tetramerization domain mandates a conformational switch upon DNA binding. Waterman JL; Shenk JL; Halazonetis TD EMBO J; 1995 Feb; 14(3):512-9. PubMed ID: 7859740 [TBL] [Abstract][Full Text] [Related]
40. p32 is a negative regulator of p53 tetramerization and transactivation. Ghate NB; Kim J; Shin Y; Situ A; Ulmer TS; An W Mol Oncol; 2019 Sep; 13(9):1976-1992. PubMed ID: 31293051 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]